title: Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.
abstract: Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis. Local and distant recurrences occur in a subset of tumors classified as 'aggressive' ACC (aACC), as opposed to 'non-aggressive' ACC (naACC). In this study, we investigated whether tissue and serum microRNAs (miRNAs) are predictive of ACC prognosis. Tissue miRNA expression profiles were determined using microarrays in a test series of six adrenocortical adenomas (ACAs), six naACCs, and six aACCs. Eight miRNAs were selected for further validation by quantitative RT-PCR (ten ACAs, nine naACCs, nine aACCs, and three normal adrenals). Serum levels of five miRNAs were measured in samples from 56 subjects (19 healthy controls (HC), 14 ACA, nine naACC, and 14 aACC patients). MiR-195 and miR-335 levels were significantly decreased in both tumor and serum samples of ACC patients relative to ACA patients or HC. MiR-139-5p and miR-376a levels were significantly increased in aACC compared with naACC patients in tumor samples only. Tissue miR-483-5p was markedly upregulated in a majority of ACC compared with ACA patients or HC, but most importantly, serum miR-483-5p was detected only in aACC patients. High circulating levels of miR-483-5p or low circulating levels of miR-195 were associated with both shorter recurrence-free survival (P=0.0004 and P=0.0014 respectively) and shorter overall survival (P=0.0005 and P=0.0086 respectively). In conclusion, this study reports for the first time that circulating miR-483-5p and miR-195 are promising noninvasive biomarkers with a highly specific prognostic value for the clinical outcome of ACC patients.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale, 17 Rue des Martyrs, Grenoble Cedex 09, France.
authors.forename: O
authors.initials: O
authors.lastname: Chabre
authors.forename: R
authors.initials: R
authors.lastname: Libé
authors.forename: G
authors.initials: G
authors.lastname: Assie
authors.forename: O
authors.initials: O
authors.lastname: Barreau
authors.forename: J
authors.initials: J
authors.lastname: Bertherat
authors.forename: X
authors.initials: X
authors.lastname: Bertagna
authors.forename: J-J
authors.initials: JJ
authors.lastname: Feige
authors.forename: N
authors.initials: N
authors.lastname: Cherradi
mesh_terms: D000293:Adolescent; D000306:Adrenal Cortex Neoplasms / Q000235:genetics / Q000378:metabolism*; D018268:Adrenocortical Carcinoma / Q000235:genetics / Q000378:metabolism*; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000378:metabolism*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs
keywords: adrenocortical carcinoma; biomarker; circulating miRNA; diagnosis; prognosis